High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: Long-term results

Journal of Clinical Oncology

Volumn 15, Issue 4, 1997, Pages 1302-1308

  Legros, M ^a   Dauplat, J ^a   Fleury, J ^a   Cure, H ^a   Suzanne, F ^a   Chassagne, J ^a   Bay, J O ^a   Sol, C ^a   Canis, M ^a   Condat, P ^a   Choufi, B ^a   Tavernier, F ^a   Glenat, C ^a   Chollet, P ^a   Plagne, R ^a  

^a CENTRE JEAN PERRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; MESNA; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; BONE MARROW APLASIA; BONE MARROW RESCUE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG FEVER; DRUG MEGADOSE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; SECOND LOOK SURGERY; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE;

EID: 17344382260     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.4.1302     Document Type: Article

References (37)

1. Ozols RF, Young RC: Chemotherapy of ovarian cancer. Semin Oncol 18:222-232, 1991
2. Runowicz CD: Advances in the screening and treatment of ovarian cancer. CA 42:327-349, 1992
3. Alberts DS, Green SG, Hannigan EV, et al: Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stage III and IV ovarian cancer. J Clin Oncol 10:706-717, 1992
4. McGuire WP, Hoskins WJ, Brady MF, et al: A phase III trial comparing cisplatin/cytoxan and cisplatin/Taxol in advanced ovarian cancer. Proc Am Soc Clin Oncol 12:255, 1993 (abstr)
5. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, et al: Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 27:1367-1372, 1991
6. Richardson GS, Sculy RE, Nikrui N, et al: Common epithelial cancer of the ovary. N Engl J Med 312:415-424, 1985
7. Berek JS, Hacker NF: Staging and second-look operations in ovarian cancer, in Alberts DS, Surwitt EA (eds): Ovarian Cancer. Boston, MA, Martinus Nijkoff, 1985, pp 109-127
8. Ozols RF: Treatment of ovarian cancer: Current status. Semin Oncol 21:1-9, 1994
9. Omura GA, Bundy BN, Berek JS, et al: Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma. A Gynecologic Oncology Group study. J Clin Oncol 7:457-465, 1989
10. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, et al: Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 5:1157-1168, 1987
11. Levin L, Hryniuk WM: Dose intensity analysis of chemotherapy regimens in ovarian cancer. J Clin Oncol 5:756-760, 1987
12. Mulder POM, Sleijfer DT, Willemse PHB, et al: High-dose cyclophosphamide or melphalan with escalation doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors. Cancer Res 49:4654-4658, 1989
13. Shea TC, Flaherty M, Elias A, et al: A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 7:651-661, 1989
14. Shpall EJ, Clark-Pearson D, Soper JT, et al: High dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. Gynecol Oncol 38:386-391, 1990
15. Viens P, Maraninchi D, Legros M, et al: High dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: A retrospective analysis of 35 patients treated in France. Bone Marrow Transplant 5:227-233, 1990
16. Menichella G, Pierelli L, Foddai ML, et al: Autologous blood stem cell harvesting and transplantation in patients with advanced ovarian cancer. Br J Haematol 79:444-450, 1991
17. Shinozuka T, Murakami M, Miyamoto T, et al: High-dose chemotherapy with autologous bone marrow transplantation in ovarian cancer. Proc Am Soc Clin Oncol 10:193, 1991 (abstr)
18. Lotz JP, Machover A, Bellaiche A, et al: Tandem high-dose chemotherapy with VM26, ifosfamide and carboplatin with ABMT for patients with stage III-IV ovarian cancer. Proc Am Soc Clin Oncol 12:25, 1993 (abstr)
19. Stiff P, Bayer RA, Camarda M, et al: A phase II trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: Analysis of risk factors for clinical outcome. Gynecol Oncol 57:278-285, 1995
20. Legros M, Fleury J, Curé H, et al: New method for stem cell quantification: Applications to the management of peripheral blood stem cell transplantation. Bone Marrow Transplant 15:1-8, 1995
21. Adair CG, Burns DT, Crockard AD, et al: Modified extraction and chromatography for the measurement of plasma melphalan by ion-pair high-performance liquid chromatography. J Chromatogr 336:429-433, 1984
22. Bannister SJ, Chang Y, Sternson LA, et al: Atomic absorption spectrophotometry of free circulating platinum species in plasma derived from cis-dichlorodiammineplatinum(II). Clin Chem 24:877-880, 1978
23. Facchinetti T, D'Incalci M, Martelli G, et al: Simple and sensitive method for the determination of cyclophosphamide by means of a nitrogen-phosphorus-selective detector. J Chromatogr 145:315-318, 1978
24. Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958
25. Mantell M: Evaluation of survival data and two-rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
26. Piver MS: Ovarian carcinoma. A decade of progress. Cancer 54:2706-2715, 1984
27. Spitzer G, Dicke K, Zander AR, et al: High-dose chemotherapy with autologous bone marrow transplantation. Cancer 54:1216-1225, 1984
28. Maraninchi D, Abecacis M, Gastaut JA, et al: High-dose melphalan with autologous bone marrow rescue for the treatment of advanced adult solid tumors. Cancer Treat Rep 68:471-479, 1984
29. Einhorn N: Acute leukemia after chemotherapy (melphalan). Cancer 41:444-447, 1978
30. Lidor YJ, Shpall EJ, Peters WP: Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer. Int J Cancer 49:704-710, 1991
31. Ozols RF, Ostchega Y, Curt G, et al: High-dose carboplatin in refractory ovarian cancer patients. J Clin Oncol 5:197-201, 1987
32. Shea TC, Storniolo AM, Mason JR, et al: A dose-escalation study of carboplatin/cydophosphamide/etoposide along with autologous bone marrow or peripheral blood stem cell rescue. Semin Oncol 19:139-144, 1992
33. Bishop JF: Current experience with high-dose carboplatin therapy. Semin Oncol 19:150-154, 1992
34. Kessinger A, Armitage JO: The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood 77:211-213, 1991
35. Siena S, Bregni M, Brando B, et al: Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 77:400-409, 1991
36. Sheridan WP, Begley CG, Juttner CA, et al: Effect of peripheral blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 339:640-644, 1992
37. Shpall EJ, Stemmer SM, Bearman SI, et al: High dose chemotherapy with autologous bone marrow support for the treatment of epithelial ovarian cancer, in Markman, Hoskins (eds): Cancer of the Ovary. New York, NY, Williams and Wilkins, 1993, pp 327-338